\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes Culture and society Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment Joint Research Center EIT Missions New European Bauhaus Horizon Europe Green DealOn 15 September 2021, the European Commission has adopted the New European Bauhaus Communication. This communication plan sets out the framework, core principles and key actions that will drive the New European Bauhaus forward. The New European Bauhaus translates the European Green Deal into a tangible and positive experience in which all Europeans can participate and progress together. The New European Bauhaus initiative has moved from the co-design phase to the delivery phase. A report on the co-design phase can be found in Annex 1 of the New European Bauhaus Communication.
For 2021-2022, 85 million euros will be mobilised for New European Bauhaus projects through different EU funding programmes (including Horizon Europe). An overview of the calls dedicated to the New European Bauhaus can be found in Annex 2 of the New European Bauhaus Communication.
Further reading can also be found on the New European Bauhaus Website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
